Author

Jan Manarite

Observed names: J. Manarite, Manarite, Jan

OpenAlex ID: A5025899387

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer: A Patient and Caregiver Perspective and Plain Language Summary of the ARASENS Trial

2022 · Matthew R Smith, Maha Hussain, et al. · Future Oncology · 15

A patient-driven clinicogenomic partnership for metastatic prostate cancer

2022 · Jett Crowdis, Sara Balch, et al. · Cell Genomics · 11

1652P SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)

2024 · D. Rathkopf, M. Dallos, et al. · Annals of Oncology · 2

Experience with the US health care system for Black and White patients with advanced prostate cancer

2023 · Emily M. Rencsok, Konrad H. Stopsack, et al. · Cancer · 1

Phase II Study of an Androgen Receptor Pathway Inhibitor + Atezolizumab + Gonadotropin-Releasing Hormone Analog and Stereotactic Body Radiotherapy in Hormone-Sensitive Metastatic Prostate Cancer

2026 · Matthew Dallos, Mark Stein, et al. · JCO oncology advances.

433 Tumor and circulating immune dynamics in prostate cancer treated with PD-L1 blockade, radiation and hormonal therapy: a multiparametric translational analysis from the SAABR trial

2025 · Matthew Dallos, Patrick McCann, et al. · Journal for ImmunoTherapy of Cancer

Ip04-31 Challenges and Unmet Needs of Caregivers for Patients With Prostate Cancer: a Us-based Quantitative Survey

2025 · Zachary Klaassen, Jan Manarite, et al. · The Journal of Urology

Works count: 18

Citation count: 29

H-index: 2

I10-index: 2